Zenas BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	500.22	110.64	319.74	56.86	67.21
Short-Term Investments	216.98	232.55	31.02	-	-
Cash & Short-Term Investments	717.21	343.19	350.77	56.86	67.21
Cash Growth	129.59%	-2.16%	516.93%	-15.40%	-
Other Current Assets	12.96	7.98	5.16	2.95	1.24
Total Current Assets	730.16	351.17	355.92	59.8	68.44
Net Property, Plant & Equipment	1.12	1.39	1.19	1.01	1.8
Long-Term Investments	1.34	17.27	-	-	-
Other Long-Term Assets	15.06	13.81	12.86	7.36	4.33
Total Assets	747.68	383.64	369.97	68.18	74.58
Accounts Payable	8.94	7.11	17.14	5.4	5.82
Accrued Expenses	51.18	54.42	39.37	17.31	19.44
Current Portion of Leases	1.04	1.12	0.79	0.56	0.72
Total Current Liabilities	61.16	62.65	57.29	23.26	25.97
Long-Term Debt	265.72	-	-	-	-
Long-Term Leases	0.08	0.21	0.22	0.26	0.81
Other Long-Term Liabilities	84.9	78.64	-	20.3	-
Total Long-Term Liabilities	350.69	78.85	0.22	20.56	0.81
Total Liabilities	411.85	141.5	57.51	43.82	26.78
Common Stock	-	-	0	-	-
Additional Paid-in Capital	1,182	1,007	699.65	4.65	1.03
Accumulated Other Comprehensive Income	-0.38	-0.06	0.19	0.04	-0.04
Retained Earnings	-	-	-387.39	-230.4	-193.28
Total Common Shareholders' Equity	1,182	1,007	312.46	-225.72	-192.29
Minority Interest	-	-	-	250.09	240.09
Shareholders' Equity	1,182	1,007	312.46	24.37	47.8
Total Liabilities & Equity	747.68	383.64	369.97	68.18	74.58
Total Debt	266.83	1.33	1	0.81	1.53
Net Cash (Debt)	450.38	341.87	349.76	56.04	65.68
Net Cash Growth	31.74%	-2.26%	524.09%	-14.67%	-
Net Cash Per Share	9.35	7.64	7.82	0.04	0.04
Book Value	1,182	1,007	312.46	-225.72	-192.29
Book Value Per Share	24.54	22.52	6.99	-0.15	-0.13
Tangible Book Value	1,182	1,007	312.46	-225.72	-192.29
Tangible Book Value Per Share	24.54	22.52	6.99	-0.15	-0.13

SEC Filings: 10-K · 10-Q